Sophia Johannisson

Sophia Johannisson

Auto-generated profile, based on publicly available information

Sophia Johannisson

Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
TRTorben Ramcke
Torben Ramcke
SJSophia Johannisson
Sophia Johannisson
EVElisabeth Vicari
Elisabeth Vicari
AEAlexander Enk
Alexander Enk
EHEva Hadaschik
Eva Hadaschik

13 November 2025 in bioRxiv
Verified
Preprint
Open access
SDSören Dräger
Sören Dräger
MSMareile Schlotfeldt
Mareile Schlotfeldt
LVLeonie Voss
Leonie Voss
SJSophia Johannisson
Sophia Johannisson
MRMichael Radziewitz
Michael Radziewitz
KBKatja Bieber
Katja Bieber
Neutrophils are key effector cells in antibody-mediated autoimmune diseases, contributing to inflammation via the release of reactive oxygen species (ROS). Extracellular signal-regulated kinase 5 (ERK5), a member of the MAPK family, is expressed in neutrophils but its role in autoimmune disease pathogenesis remains unclear. We investigated the functional relevance of ERK5 in antibody-mediated autoimmune diseases by comparing neutrophil-dependent (epidermolysis bullosa acquisita, EBA; serum transfer arthritis, STA) and neutrophil-independent (immune thrombocytopenia, ITP) murine models using the small-molecule ERK5 inhibitor XMD8-92. In vitro , pharmacological ERK5 inhibition specifically reduced neutrophil ROS release and CD62L shedding without affecting adhesion, chemotaxis, or CD18 expression. No major effects on viability were observed. In vivo , ERK5 inhibition with XMD8-92 significantly ameliorated antibody transfer-induced EBA, supporting a critical role of neutrophil-derived ROS in disease pathogenesis. In STA and ITP, ERK5 inhibition did not affect clinical outcomes. Together, these findings highlight ERK5 as a regulator of neutrophil ROS release and a potential therapeutic target in ROS-driven autoimmune diseases such as EBA.

19 November 2025 in bioRxiv
Verified
Preprint
Open access
MSMareile Schlotfeldt
Mareile Schlotfeldt
LVLeonie Voss
Leonie Voss
AMAdrian Pablo Mansini
Adrian Pablo Mansini
DMDaniel Mehlberg
Daniel Mehlberg
SJSophia Johannisson
Sophia Johannisson
KBKatja Bieber
Katja Bieber
Background: Cyclin-dependent kinases (CDKs) are involved in basic cellular processes like regulation of cell-cycle progression and transcription. However, recent data also indicate a specific role in terminally differentiated neutrophils by promoting reactive oxygen species (ROS) release, degranulation, neutrophil extracellular trap formation, or apoptosis. Since these mechanisms are implicated in multiple autoimmune diseases, we aimed to delineate the role of CDKs in IC-mediated autoimmune diseases both in vitro and in vivo . Methods: We analyzed CDK gene expression in unstimulated and immune complex (IC)-stimulated neutrophils. Subsequently, we investigated the effect of pharmacological CDK inhibition on IC-activated neutrophil functions. To analyze the inhibitors in a more translational approach, we proceeded with the systemic and topical application of the effective inhibitors in a murine antibody transfer-induced local epidermolysis bullosa acquisita (EBA) model. The most efficient inhibitor, MC180295, was validated in two other IC-mediated models of autoimmune disease: Serum-transfer arthritis (STA), which also, but not exclusively, depends on neutrophils and immune thrombocytopenia (ITP), which is considered less neutrophil-dependent. Results: We found 14 CDKs expressed in unstimulated cells, while the IC-stimulation showed an upregulation of CDK2 and CDK4 expression. Inhibitors selectively targeting CDK1, CDK2, CDK4/6, CDK7, CDK9, CDK11, and CDK12 showed effects on different neutrophil functions (surface activation marker expression, ROS release, adhesion, apoptosis) in vitro . In the predominantly neutrophil-driven EBA model, we observed a reduction of disease severity upon treatment with CDK7, CDK9, or CDK11 inhibitors. Inhibiting these CDKs with topical THZ2, MC180295, or OTS964, respectively, also improved the clinical phenotype. In line with our hypothesis, MC180295 impaired the development of STA, but not ITP. Conclusions: CDK7, CDK11, and especially CDK9 inhibition s how therapeutic potential in IC-driven neutrophil-mediated diseases such as rheumatoid arthritis and EBA.